Study of PlasmaCap IG in Adults and Children With PIDD

Inclusion Criteria: * Subject has a confirmed clinical diagnosis of a PIDD, which requires treatment with IGIV: * Subject/guardian has provided written informed consent (and assent, as applicable). * Subject is between the ages of 2 and 70 years. * Subject has received regular IGIV therapy at 21- or 28-day (±4 days) intervals for at least three consecutive months at a dose between 300-900 mg/kg/month prior to Screening or; * Subject has received commercial SCIG at a dose of 300-900 mg/kg/month on any dosing schedule for at least 12 consecutive weeks prior to Screening. Subjects on SCIG must have received and tolerated IGIV treatment prior to SCIG treatment. * Subject has a documented trough of ≥500 mg/dL in the 6 months prior to screening. * Females of childbearing potential must be willing to use an effective form of birth control (eg, oral contraceptives) for the duration of the study, per IRB/REB guidelines. * Subject agrees to comply with the requirements of the protocol. Exclusion Criteria: * Subject has secondary immunodeficiency. * Subject has history of thrombotic events, such as deep vein thrombosis, myocardial infarction, cerebrovascular accident, pulmonary embolism, etc within the year prior to screening. * Subject has had an immune globulin associated arterial or venous thrombotic/thromboembolic event (TEE) within 7 days of infusion or a TEE that is not associated with an immune globulin within one year of screening. * Subject has received blood products (excep…